1. Trials Update
May 2019

3. EuroEwings 2012

4. EE 2012 Now closed, R1 recruited over its target of 600
Webex meetings ? Next week
Letter to investigators
VDC/IE is superior to VIDE induction
Next first line Ewings trial still in development
Good UK recruitment
Biological samples – good, not great

5. Local control audit
RT alone 22%
Surgery alone 28%
Both 50%

6. RECCUR

7. RECCUR Relapsed Ewings Measurable disease, biological, QoL 4 arms:
can elect not to use 1 for specific patient
Irinotecan/Temozolomide
Ifosfamide
Gemcitabine/Docetaxel (poorer RR and efs)
Cyclophosphamide/Topotecan

8. Quality of Life SAM – Sarcoma Assessment Measure
EORTC - in development

9. SAM Sarcoma Assessment Measure Developing a QoL tool for Sarcoma
In phase II (1000 pts)
Hope that this will be available for use in trials
40 for Glasgow

10. Rhabdomyosarcoma Long running trials Most participants are paediatric
Guide our adult practice
RMS 2005
EpSSG etc

11. FaR RMS Children and young adults (? Up to 29) Alveolar and Embryonal
(based on fusion status)
All stages
PET CT at diagnosis
Very complicated RT section with randomisations

12. FaR RMS Very high risk: IVADo +/- irinotecan
High Risk: IVA +/- irinotecan
Maintenance: 6 v 12 v 24 months Cyclo/Vin
Risk group dependant
Relapse: VI v VIT or similar (? Regorafanib)

13. Retroperitoneal Sarcoma
Interest in improving outcomes by adding something to surgery
Various papers, single institution publications
Conflicting outcomes
Previous American Study failed to recruit

14. STRASS 1 Operable retroperitoneal sarcoma RT pre op or no radiotherapy
No safety concerns between the 2 arms
Still not reported, due at ASCO next month
Tried to open, too difficult to get through RT dept

15. STRASS 2 In development, final protocol soon.
Chemotherapy question. PET CT, MRI, Biological
Neoadj chemo x 3 for operable
High grade Leiomyosarcoma (DTIC/adria)
High grade and De diff Liposarcoma (ifos/adria)
Primary endpoint:
dfs powered for 20% improvement
From 29% to 48%

16. GIST 3 v 5 year trial SSG XXII
Recruiting in Glasgow, recruitment extended to March 2020
Have to have right pathology, mitotic rate and molecular analysis
4 patients on, a few more coming soon

17. Deciphera Phase 3 DCC 2618 or sunitinib After imatinib failure
Open in Glasgow

18. Voyager Avapritinib v Regorafanib Advanced GIST
After imatinib, can have had up to 2 other TKIs

19. Radiotherapy trials Only 1
Advent of protons in UK is likely to have an impact

20. IMRiS Radiotherapy Largest cohort closed (STS limb) Open still for:
Planning, delivery and acute events
Largest cohort closed (STS limb)
Open still for:
Ewings of pelvis or spine
Other bone tumours of Spine

21. ICONIC Osteosarcoma In absence of a therapeutic trial
Data collection for all patients
Coupled with pathological material
May offer insights, allow identification of targets
Would like to open across Scotland

22. TAPPAS
Angiosarocma
Pazopanib v pazo plus something
Tried hard to open

23. Larrys Liposarcoma study EORTC 1202 STBSG
Cabazitaxel in metastatic or inoperable locally advanced de differentiated Liposarocma
Phase II

24. There are many others
Particularly early phase trials run in 1 or 2 centres
Look at:
CRUK trials finder
Sarcoma UK website
NCRI portfolio maps
or contact one of the London Oncologists